Citadel Advisors
KYTX icon

Citadel Advisors’s Kyverna Therapeutics KYTX Stock Holding History

Citadel Advisors’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.32M Buy
147,627
+89,501
+154% +$795K ﹤0.01% 7526
2026
Q1 		$502K Sell
58,126
-217,320
-79% -$1.81M ﹤0.01% 9303
2025
Q4 		$2.59M Buy
275,446
+257,780
+1,459% +$1.91M ﹤0.01% 5445
2025
Q3 		$106K Sell
17,666
-307,723
-95% -$1.23M ﹤0.01% 11813
2025
Q2 		$999K Sell
325,389
-668,231
-67% -$1.65M ﹤0.01% 7086
2025
Q1 		$1.92M Buy
993,620
+831,301
+512% +$2.46M ﹤0.01% 5615
2024
Q4 		$607K Buy
162,319
+24,580
+18% +$118K ﹤0.01% 8135
2024
Q3 		$674K Sell
137,739
-90,398
-40% -$697K ﹤0.01% 7631
2024
Q2 		$1.71M Sell
228,137
-295,606
-56% -$4.52M ﹤0.01% 5608
2024
Q1 		$13M Buy
+523,743
New +$14.6M ﹤0.01% 2584

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Citadel Advisors's KYTX Position: Q2 2026 in Review

Citadel Advisors increased its Kyverna Therapeutics (KYTX) stake by 154% in Q2 2026, buying an estimated $795K and bringing the position to 147,627 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #7526.

Citadel Advisors first reported a position in KYTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $13M in Q1 2024. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Citadel Advisors held 147,627 shares of Kyverna Therapeutics worth $1.32M as of Q2 2026.
  • Citadel Advisors bought 89,501 Kyverna Therapeutics shares in Q2 2026, an estimated $795K.
  • Kyverna Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #7526 holding.
  • Citadel Advisors first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Citadel Advisors's Kyverna Therapeutics position peaked at $13M in Q1 2024.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.